S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
“Cup-like” blasts and NPM1 and FLT3 (ITD) mutations in acute myeloid leukemia (AML)
TL;DR: Flow cytometry studies demonstrate that the blasts were positive for CD33, CD13, CD117 and MPO confirming the diagnosis of acute myeloid leukemia (AML), and the unusual morphology of blasts with cuplike nuclear indentation has been described in a subset of AML with NPM1 and FLT3 mutations.
Journal ArticleDOI
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model
Stefan Faderl,Carlos Bueso-Ramos,Zhiming Liu,Ashutosh Pal,William Bornmann,Diana V. Ciurea,David Harris,Inbal Hazan-Halevy,Hagop M. Kantarjian,Zeev Estrov +9 more
TL;DR: APcK110 is a novel kit kinase inhibitor with anti-AML activity in vitro and in vivo and further evaluation in toxicology and clinical studies is warranted.
Journal ArticleDOI
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia
Isam A. Abdel-Karim,William Plunkett,Susan O'Brien,Francis J. Giles,Deborah A. Thomas,Stefan Faderl,Farhad Ravandi,Mary Beth Rios,Min Du,Karen B. Schneck,Victor J. Chen,Boris Lin,Steven J. Nicol,Hagop M. Kantarjian +13 more
TL;DR: While tolerable, pemetrexed monotherapy had limited activity in this highly refractory population of acute myeloid or relapsed acute leukemia, and no firm conclusion can be made regarding TS saturation in tumor cells.
Journal ArticleDOI
Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy
Farhad Ravandi,Deborah A. Thomas,Susan O'Brien,Rebecca Garris,Stefan Faderl,Jianqin Shan,Gautam Borthakur,Jan A. Burger,Alessandra Ferrajoli,Partow Kebriaei,Richard E. Champlin,Zeev Estrov,Sa A. Wang,Jeffrey L. Jorgensen,Rajyalakshmi Luthra,Jorge E. Cortes,Hagop M. Kantarjian +16 more
TL;DR: MRD monitoring by PCR and MFC can identify pts who may benefit from intensification of treatment with an allogeneic stem cell transplant in first CR, and achieving a negative MRD status by MFC was associated with a significantly improved survival.
Journal ArticleDOI
Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL).
Deborah A. Thomas,Hagop M. Kantarjian,Stefan Faderl,William G. Wierda,Jorge E. Cortes,Jan A. Burger,Alessandra Ferrajoli,Zeev Estrov,Charles Koller,Marina Konopleva,Gautam Borthakur,Elias Jabbour,Farhad Ravandi,Tapan M. Kadia,Guillermo Garcia-Manero,Steven M. Kornblau,Michael Andreeff,Rebecca Garris,Michael J. Keating,Susan O'Brien +19 more
TL;DR: The maintenance phase was extended to 30 months with additional intensifications owing to late relapses after completion of POMP therapy, and rituximab improved outcome compared to historical experience with hyper-CVAD alone.